##  [INVIMA Resolution 2026025611 of May 21, 2026: Contingency Plan for Rationalization and Automation of Sanitary Registration Procedures](/mandate/invima-resolution-2026025611-of-may-21-2026-contingency-plan-for-rationalization-and-automation-of-sanitary-registration-procedures) 

May 21, 2026

INVIMA issued Resolution No. 2026025611 on 21-May-2026, adopting a contingency plan aimed at rationalizing, simplifying, and automating procedures for the issuance, modification, and management of sanitary registrations and related regulatory processes. The plan introduces a risk-based regulatory approach, AI-supported tools, and prioritization mechanisms to address backlogs and ensure medicine availability.

**Policy Focus:**

- Adoption of a contingency plan for rationalization, simplification, automation, and digital transformation of sanitary registration and variation procedures.

**Scope:**

- Applicable to all registration, monitoring, and control procedures managed by INVIMA's Directorate of Medicines and Biological Products, covering biologics, medical gases, medicinal products, and homeopathic drugs.

**Key Requirements / Provisions:**

- Risk-Based Model: Post-market/control verification approach maintaining existing technical and quality requirements.
- Prioritization Mechanisms: Manufacturing site additions/substitutions and manufacturer transfers prioritized to prevent medicine shortages.
- Accelerated Pathways: New drug registration applications not requiring Commission Review or BD/BE studies eligible for accelerated assessment.
- Expanded Scope: Registration cancellations/suspensions, import-export authorizations, and administrative appeals included.
- AI Integration: Formal incorporation of AI tools for application classification, prioritization, and monitoring with mandatory human oversight; no AI-based regulatory decision-making.
- GMP Certificate Acceptance: Electronic verification through official foreign regulatory authority websites accepted as evidence.

**Regulatory Goals:**

- Reduce procedural backlogs and improve market access timelines.
- Incorporate digital transformation and AI in regulatory operations.
- Ensure medicine supply continuity.



[Consult Now](/webform/consult%0A?url=https://preprod.freyrsolutions.com/markdownify/node/13670)



Select Mandate HA

[INVIMA](/mandate-by-ha/invima)

 

Select Mandate Function

[Regulatory Affairs](/mandate-by-function/regulatory-affairs)